Standard BioTools (LAB)

• Market cap: $558M
• 1 day: -5.06%
• 5 days: -31.82%
• 1 month: -21.05%
• 3 months: -21.47%
• 6 months: -41.86%
• Year to date: -32.43%
• 1 year: -33.92%
• 5 years: -35.62%
• 10 years: -95.15%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Employees: 539

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

8% more capital invested

Capital invested by funds: $502M [Q2] → $541M (+$39.4M) [Q3]

0.98% less ownership

Funds ownership: 76.53% [Q2] → 75.55% (-0.98%) [Q3]

2% less funds holding

Funds holding: 142 [Q2] → 139 (-3) [Q3]

12% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 25

20% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 46

21% less call options, than puts

Call options by funds: $72K | Put options by funds: $91K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2.50 67% upside
• Avg. target: $2.50 67% upside
• High target: $2.50 67% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

TD Cowen Daniel Brennan 50% 1-year accuracy 3 / 6 met price target

67% upside $2.50

Buy Maintained

31 Oct 2024